Multidisciplinary treatment of rectal cancer in 2014: Where are we going?

被引:5
|
作者
Andrea Vignali [1 ]
Paola De Nardi [1 ]
机构
[1] Department of Surgery, San Raffaele Scientific Institute, Vita Salute University
关键词
Rectal cancer; Cancer staging; Cancer restaging; Neoadjuvant chemoradiation; Response; Treatment; Local control; Local excision; Complete pathologic response; Rectal cancer surgery;
D O I
暂无
中图分类号
R735.3 [肠肿瘤];
学科分类号
100214 ;
摘要
In the present review we discuss the recent developments and future directions in the multimodal treatment of locally advanced rectal cancer, with respect to staging and re-staging modalities, to the current role of neoadjuvant chemo-radiation and to the conservative and more limited surgical approaches based on tumour response after neoadjuvant combined therapy. When initial tumor staging is considered a high accuracy has been reported for T pre-treatment staging, while preoperative lymph node mapping is still suboptimal. With respect to tumour re-staging, all the current available modalities still present a limited accuracy, in particular in defining a complete response. The role of short vs long-course radiotherapy regimens as well as the optimal time of surgery are still unclear and under investigation by means of ongoing randomized trials. Observational management or local excision following tumour complete response are promising alternatives to total mesorectal excision, but need further evaluation, and their use outside of a clinical trial is not recommended.The preoperative selection of patients who will benefit from neoadjuvant radiotherapy or not, as well as the proper identification of a clinical complete tumour response after combined treatment modalities,will influence the future directions in the treatment of locally advanced rectal cancer.
引用
收藏
页码:11249 / 11261
页数:13
相关论文
共 50 条
  • [21] Cannabinoids in the treatment of cancer anorexia and cachexia: Where have we been, where are we going?
    Seymour-Jackson, Emily
    Laird, Barry J. A.
    Sayers, Judith
    Fallon, Marie
    Solheim, Tora S.
    Skipworth, Richard
    ASIA-PACIFIC JOURNAL OF ONCOLOGY NURSING, 2023, 10
  • [22] Biomarkers in Breast Cancer: Where Are We and Where Are We Going?
    Duffy, Michael J.
    Walsh, Siun
    McDermott, Enda W.
    Crown, John
    ADVANCES IN CLINICAL CHEMISTRY, VOL 71, 2015, 71 : 1 - 23
  • [23] Prostate cancer immunotherapy: where are we and where are we going?
    De Velasco, Marco A.
    Uemura, Hirotsugu
    CURRENT OPINION IN UROLOGY, 2018, 28 (01) : 15 - 24
  • [24] Diet and cancer prevention: Where we are, where we are going
    Gonzalez, Carlos A.
    Riboli, Elio
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2006, 56 (02): : 225 - 231
  • [25] Multimodal treatment of gastric cancer in the west: Where are we going?
    Daniele Marrelli
    Karol Polom
    Giovanni de Manzoni
    Paolo Morgagni
    Gian Luca Baiocchi
    Franco Roviello
    World Journal of Gastroenterology, 2015, 21 (26) : 7954 - 7969
  • [26] Breast cancer causes and treatment: where are we going wrong?
    Seymour, Colin B.
    Mothersill, Carmel
    BREAST CANCER-TARGETS AND THERAPY, 2013, 5 : 111 - 119
  • [27] Multimodal treatment of gastric cancer in the west: Where are we going?
    Marrelli, Daniele
    Polom, Karol
    de Manzoni, Giovanni
    Morgagni, Paolo
    Baiocchi, Gian Luca
    Roviello, Franco
    WORLD JOURNAL OF GASTROENTEROLOGY, 2015, 21 (26) : 7954 - 7969
  • [28] Prostate Cancer: Where We Have Been, Where We Are, and Where We Are Going
    D'Amico, Anthony V.
    SEMINARS IN RADIATION ONCOLOGY, 2013, 23 (03) : 155 - 156
  • [29] Prostate Cancer: Where We Have Been, Where We Are, Where We Are Going
    Michael K. Brawer
    World Journal of Surgery, 2000, 24 : 1200 - 1204
  • [30] Prostate cancer: Where we have been, where we are, where we are going
    Brawer, MK
    WORLD JOURNAL OF SURGERY, 2000, 24 (10) : 1200 - 1204